[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

142

1 proved to be more effective. So that we don't have to
2 wait for the perfect vaccine to monitor the trial.
3 Now, if there's a safety issue, you're
4 going to find it out rapidly in a large, simple trial.
5 A lot of people will have the side effect.
6 The other big thing is large, simple
7 trials have also been done in other areas. BCG, the
8 British MRC, has a tradition of doing trials somewhere
9 between 50 and 80 thousand subjects in the Gambia and
10 Zaire and in Madras, India.
11 The National Iron Institute in this
12 country did a large trial in India, where 16,000 were
13 randomized to Vitamin A and no Vitamin A; within one
14 year, the absolutely clear results. Similar trials
15 have been done in Indonesia, Nepal, and a similar one
16 is being done in Egypt.
17 So I would endorse this concept that Mark
18 Harrington and Susan Ellenberg put up as not the only
19 way to go, but certainly a major way to go
20 complemented by other things that are being done.
21 There's no reason why in the context of
22 these trials a few specialized centers couldn't gather
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHOOE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]